Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALS-008176 in RSV challenge model
NCT02094365Phase 2Completed
- Sponsor
- Alios BioPharma
- Start
- Mar 2014
- Primary completion
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lumicitabine in respiratory syncytial virus infection (RSV) (4 arms), sponsored by Alios BioPharma. Primary endpoint: Area Under the Curve for Viral Load at Day 12. Started Mar 2014; status: completed.
02
Drugs
lumicitabine
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT02094365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02094365.